Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib …

N Reguart, R Rosell, F Cardenal, AF Cardona, D Isla… - Lung cancer, 2014 - Elsevier
Objectives Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone
deacetylase inhibitor with demonstrated antiproliferative effects due to drug-induced …
被引用次数：97 相关文章

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib …

N Reguart, R Rosell, F Cardenal, AF Cardona… - Lung …, 2014 - portalrecerca.uab.cat
Objectives: Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone
deacetylase inhibitor with demonstrated antiproliferative effects due to drug-induced …

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib …

N Reguart, R Rosell, F Cardenal… - Lung cancer …, 2014 - pubmed.ncbi.nlm.nih.gov
Objectives Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone
deacetylase inhibitor with demonstrated antiproliferative effects due to drug-induced …

[引用][C] Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after …

N Reguart, R Rosell, F Cardenal, AF Cardona, D Isla… - Lung Cancer, 2014 - cir.nii.ac.jp
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression …

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib …

N Reguart, R Rosell, F Cardenal, AF Cardona, D Isla… - Lung Cancer, 2014 - infona.pl
Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone deacetylase
inhibitor with demonstrated antiproliferative effects due to drug-induced accumulation of …

[引用][C] Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after …

N REGUART, R ROSELL, E CARCERENY… - Lung …, 2014 - pascal-francis.inist.fr
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression …

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib …

N Reguart, R Rosell, F Cardenal… - Lung cancer: journal …, 2014 - repository.uantwerpen.be
Objectives: Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone
deacetylase inhibitor with demonstrated antiproliferative effects due to drug-induced …

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib …

N Reguart, R Rosell, F Cardenal, AF Cardona… - Lung …, 2014 - lungcancerjournal.info
Objectives Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone
deacetylase inhibitor with demonstrated antiproliferative effects due to drug-induced …
[PDF] academia.edu

[PDF][PDF] Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after …

N Reguart, R Rosell, F Cardenal, AF Cardona, D Isla… - Lung …, 2014 - academia.edu
abstract Objectives: Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone
deacetylase inhibitor with demonstrated antiproliferative effects due to drug-induced …

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib …

N Reguart, R Rosell, F Cardenal… - Lung Cancer …, 2014 - europepmc.org
Objectives Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone
deacetylase inhibitor with demonstrated antiproliferative effects due to drug-induced …